WASHINGTON (Reuters) – Teva Pharmaceutical Industries Ltd on Tuesday won a ruling from a U.S. administrative court that helps preserve its rights to the migraine drug Ajovy.
The Patent Trial and Appeal Board rejected a challenge to three Teva patents relating to Ajovy brought by Eli Lilly and Co.
(Reporting by Jan Wolfe; Editing by Cynthia Osterman)
